Takeda purchases US biologics manufacturing plant from Baxalta
The facility will be used for the manufacture of Entyvio and other biologic products
Japanese pharmaceutical company Takeda has bought a biologics manufacturing facility in Brooklyn Park, Minnesota, US, from Baxalta.
Financial terms of the deal have not been disclosed.
Takeda said it will use the facility primarily for the manufacture of ulcerative colitis treatment Entyvio (vedolizumab) and other biologic products, allowing the company to maximise global efficiencies and further enhance the supply chain flexibility of the product.
'Takeda’s focus is providing patients access to quality therapies,' said Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda.
'Acquiring the state-of-the-art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.'
The firm said the acquisition will also provide long-term benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development.
